Selected publications

Nabers, A., Ollesch, J., Schartner, J., et al. (2016). An infrared sensor analysing label-free the secondary structure of the Abeta peptide in presence of complex fluids. J. Biophoton, 9: 224-234. https://doi.org/10.1002/jbio.201400145

Nabers A., Ollesch J., Schartner J., et al. (2016). Amyloid-β-Secondary Structure Distribution in Cerebrospinal Fluid and Blood Measured by an Immuno-Infrared-Sensor: A Biomarker Candidate for Alzheimer’s Disease. Analytical Chemistry 88 (5), 2755-2762. https://doi.org/10.1021/acs.analchem.5b04286

Nabers A., Perna L., Lange J., et. al. (2018). Amyloid blood biomarker detects Alzheimer’s disease. EMBO Mol Med. 2018 May;10(5):e8763. https://doi.org/10.15252/emmm.201708763. PMID: 29626112; PMCID: PMC5938617.

Stockmann, J., Verberk, I.M.W., Timmesfeld, N., et al. (2020). Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline. Alz Res Therapy 12, 169. https://doi.org/10.1186/s13195-020-00738-8

Beyer, L., Stocker, H., Rujescu, D., et al. (2022). Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer’s disease diagnosis within 17 years. Alzheimer’s Dement. 1- 9. https://doi.org/10.1002/alz.12745

Beyer, L., Günther, R., Koch, J.C., et al. (2021). TDP-43 as structure-based biomarker in amyotrophic lateral sclerosis. Ann. Clin. Transl. Neurol., 8: 271-277. https://doi.org/10.1002/acn3.51256

Schuler M., Gerwert G., Mann M., et al. (2025). Alpha-synuclein misfolding as fluid biomarker for Parkinson’s disease measured with the iRS platform. EMBO Mol Med. 2025 Jun;17(6):1203-1221. https:// doi.org/10.1038/s44321-025-00229-z. Epub 2025 Apr 25. PMID: 40281305; PMCID: PMC12162852.

Langenhoff L., Simon J., Weber S., et al. (2025). Misfolding of alpha-synuclein as blood-based biomarker for Parkinson´s disease. medRxiv 2025.12.19.25342662; https://doi.org/10.64898/2025.12.19.25342662.